齐拉西酮序贯治疗精神分裂症急性期30例临床疗效及安全性分析

Clinical Efficacy and Safety Analysis of Ziprasidone in Patients with Acute Phase of Schizophrenia

目的:探讨齐拉西酮序贯治疗精神分裂症急性期的临床治疗效果和安全性。方法:选取2019年1月至2020年12月上饶市第三人民医院精神分裂症急性期患者60例,按照随机数字表法分为对照组(n=30)和试验组(n=30),对照组使用口服利培酮,试验组使用齐拉西酮序贯治疗。比较两组疗效、阳性与阴性状况评分表(PANSS)、社会功能缺陷评分表(SDSS)、副反应量表(TESS)、事件相关电位、不良反应发生率变化。结果:试验组总有效率93.33%(28/30)较对照组73.33%(22/30)高(P<0.05);与对照组比较,试验组阳性特征、一般病理、阴性特征数值低(P<0.05);SDSS、TESS数值低(P<0.05);潜伏期数值低,且波幅数值高(P<0.05);不良反应发生率16.67%(5/30)与对照组26.67%(8/30)相比差异无统计学意义(P>0.05)。结论:齐拉西酮序贯治疗精神分裂症急性期效果明显,还可以改善临床症状和机体功能,调节事件相关电位,并具有安全性。

Objective:To explore the clinical efficacy and safety of ziprasidone in sequential treatment in the acute phase of schizophrenia.Methods:60 patients with acute phase of schizophrenia from January 2019 to December 2020 were divided into control group(n=30)and experiment group(n=30)according to the random number table method.Control group used oral risperidone and experiment group treated with ziprasidone.Changes of efficacy,positive and negative status score table(PANSS),social functional defect score table(SDSS),side reaction scale(TESS),event-related potential,and adverse reactions were compared between two groups.Results:The total efficiency was 93.33%(28/30)versus 73.33%(22/30)(P>0.05).In comparison with the control group,the values of positive characteristics,general pathology,and negative features in the test group were low(P<0.05);the value of SDSS and TESS in the test group was low(P<0.05);latency values were low in the test group,and the wave amplitude value was high(P<0.05);the incidence of adverse reactions of 16.67%(5/30)was not significantly changed compared with 26.67%(8/30)in the control group(P>0.05).Conclusion:Ziprasidone is highly effective in the acute phase of schizophrenia,which can also improve clinical symptoms and body function,regulate event-related potential,and has high safety.